Replies to post #224010 on Biotech Values

[DewDiligence]

XFOR -35% on ASH update:

https://finance.yahoo.com/news/x4-pharmaceuticals-presents-clinical-scientific-130000745.html

[DewDiligence]

XFOR -35% on purportedly-positive phase-2 data in chronic neutropenia:

https://www.globenewswire.com/news-release/2024/06/27/2905026/0/en/X4-Pharmaceuticals-Announces-Positive-Interim-Clinical-Data-from-Ongoing-Six-Month-Phase-2-Trial-of-Mavorixafor-in-Chronic-Neutropenia-CN-and-Initiation-of-Pivotal-Phase-3-CN-Trial.html